Cadila Healthcare has divested its entire shareholding in Bremer Pharma GmbH, Germany (Bremer), a wholly owned subsidiary of the company and consequently, Bremer ceased to be a subsidiary of the company.

The company received consideration at enterprise value of Euro 22,63,431 of which share sale value is Euro 8,27,344 and loan value (extended by Zydus International-a wholly owned subsidiary of the company) is Euro 14,36,087.

The stock had underperformed the market over the past one month till Apr. 17, 2018, rising 2.87% compared with the Sensex's 3.67% rise. It underperformed the market in past one quarter, declining 10.27% as against 1.96% fall in the Sensex.

Shares of the company declined Rs 0.5, or 0.13%, to trade at Rs 387.90. The total volume of shares traded was 7,679 at the BSE (9.52 a.m., Wednesday).